行情

ALDX

ALDX

Aldeyra
NASDAQ

实时行情|Nasdaq Last Sale

5.93
+0.01
+0.17%
盘后: 5.93 0 0.00% 16:00 09/23 EDT
开盘
6.04
昨收
5.92
最高
6.04
最低
5.73
成交量
18.96万
成交额
--
52周最高
16.70
52周最低
4.310
市值
1.64亿
市盈率(TTM)
-2.9765
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ALDX 新闻

  • Aldeyra Therapeutics Inc (ALDX) President and CEO Todd C Brady Bought $102,800 of Shares
  • GuruFocus.com.09/12 07:15
  • Aldeyra Therapeutics (ALDX) Presents At 26th Annual NewsMakers In The Biotech Industry - Slideshow
  • Seeking Alpha - Article.09/11 17:22
  • 80 Biggest Movers From Yesterday
  • Benzinga.09/11 09:11
  • What Kind Of Shareholder Appears On The Aldeyra Therapeutics, Inc.'s (NASDAQ:ALDX) Shareholder Register?
  • Simply Wall St..09/06 16:18

更多

所属板块

生物技术和医学研究
-0.69%
制药与医学研究
-0.43%

热门股票

名称
价格
涨跌幅

ALDX 简况

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.
展开

Webull提供Aldeyra Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。